Compare GSBC & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSBC | CSTL |
|---|---|---|
| Founded | 1923 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 746.4M | 597.8M |
| IPO Year | 1996 | 2019 |
| Metric | GSBC | CSTL |
|---|---|---|
| Price | $72.03 | $21.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $65.00 | $45.50 |
| AVG Volume (30 Days) | 88.8K | ★ 491.9K |
| Earning Date | 04-15-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | ★ 17.68 | N/A |
| EPS | ★ 1.58 | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | N/A | $2.42 |
| Revenue Next Year | $2.56 | $12.69 |
| P/E Ratio | $44.96 | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $53.76 | $14.59 |
| 52 Week High | $73.12 | $44.28 |
| Indicator | GSBC | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 60.90 | 51.89 |
| Support Level | $60.23 | $17.72 |
| Resistance Level | N/A | $22.18 |
| Average True Range (ATR) | 2.01 | 1.11 |
| MACD | 0.08 | 0.31 |
| Stochastic Oscillator | 81.44 | 87.84 |
Great Southern Bancorp Inc is a bank holding company. Through its subsidiaries, the company mainly offers a variety of banking and banking-related services, such as accepting deposits, granting loans and advances, offering mobile banking services, issuing debit and credit cards, safe deposit boxes, ATM facilities, and other related products and services. These services are offered through full-service retail banking offices and loan production offices located across different states in the U.S., including Missouri, Iowa, Kansas, Minnesota, Nebraska, Arkansas, and others.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.